ZTE’s Micro-Base Station Enhances CSL’s Services at Rugby Sevens 2013

SHENZHEN, China - March 27th 2013--(BUSINESS WIRE / ME NewsWire)-- ZTE Corporation ("ZTE”) (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment, network solutions and mobile devices, today announced their micro-base station solution was used to enhance Hong Kong mobile operator CSL’s communication services at the Hong Kong Stadium during the Hong Kong Rugby Sevens 2013.

The base station enhanced services throughout the tournament and allowed double the amount of data traffic and four-and-a-half times the amount of voice calls to be handled seamlessly, compared to the previous year. Over 130,000 voice calls and 230GB of data traffic were handled by the network alone with a call connection success rate of 99.9%. In addition, over 80% of full webpage loads were completed within 10 seconds, thanks to the increased capacity provided ... Read more »

European Medicines Agency has accepted for review a marketing authorisation application for the sodium glucose cotransporter-2, empagliflozin

INGELHEIM, Germany - Wednesday, March 27th 2013 [ME NewsWire]

(BUSINESS WIRE)--

EX US & UK Medical Media Only

Boehringer Ingelheim and Eli Lilly and Company today announced the European Medicines Agency (EMA) has accepted for review a marketing authorisation application (MAA) for the investigational sodium glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, for the treatment of Type 2 Diabetes (T2D) in adults. The acceptance of the MAA marks the beginning of the review process in the European Union for this potential oral diabetes treatment.

"We are pleased with the promising results shown in clinical trials of empagliflozin and are delighted that EMA has accepted our marketing authorisation application,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "Type 2 Di ... Read more »

INGELHEIM, Germany - Tuesday, March 26th 2013 [BUSINESS WIRE/ ME NewsWire]

    The U.S. Food and Drug Administration (FDA) stated that bleeding rates associated with new use of Pradaxa® (dabigatran etexilate) do not appear to be higher than those with new use of warfarin1,2

For media outside of the US, the UK & Canada only

A new perspective from the U.S. Food and Drug Administration (FDA) published in the New England Journal of Medicine1 states that the agency has not changed its recommendations regarding Pradaxa® (dabigatran etexilate), following the November 2012 Mini-Sentinel evaluations.2 The FDA stated that bleeding rates associated with new use of Pradaxa® do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY® trial.1-4 The perspective was published online on March 13, 2013.1

The Mini-Sentinel evaluated new information about the risk of serious ble ... Read more »